NCT06832410RecruitingPhase 3
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant
Source: ClinicalTrials.gov · Last updated 23 Mar 2026
Brief summary (registry, in English)
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 13 Feb 2025
- Start date
- 31 Mar 2025
- Primary completion date
- 17 Sept 2026
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Diseases
- Type 1 diabetes
- NCT number
- NCT06832410
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 10
- From 31 Mar 2025 to the primary completion date, 17 Sept 2026
- 7 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks
- Participants had \>1 kidney transplant procedure
- Other protocol defined Inclusion/Exclusion criteria may apply.
Who the study is looking for
- Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence
- Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks
- Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Toronto General Hospital - Endocrinology Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
| Vancouver General Hospital, Gordon and Leslie Diamond Health Care Centre Coordinator of this site? Confirm its status | Vancouver | Canada | Recruiting |
| King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology Coordinator of this site? Confirm its status | Riyadh | Saudi Arabia | Recruiting |
| King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology Coordinator of this site? Confirm its status | Riyadh | Saudi Arabia | Recruiting |
| UW University Hospital - Endocrinology Coordinator of this site? Confirm its status | Madison | United States | Recruiting |
| Perelman Center for Advanced Medicine - Endocrinology Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
| Montefiore Clinical and Translational Research Center - Endocrinology Coordinator of this site? Confirm its status | Pittsburgh | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.